Australian Centre for Vaccine Development and Tumour Immunology Laboratory; Department of Immunology; Queensland Institute of Medical Research; Brisbane, Australia.
Oncoimmunology. 2012 Nov 1;1(8):1440-1442. doi: 10.4161/onci.21286.
Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated malignancy that is highly prevalent in Southern China and South-East Asia. EBV-targeted immunotherapy remains a goal in the development of novel treatment strategies. A novel adenoviral polyepitope-based immunotherapy has been developed to rapidly generate high frequency EBV-specific T cells to treat patients with refractory or metastatic disease.
鼻咽癌（NPC）是一种与 Epstein-Barr 病毒（EBV）相关的恶性肿瘤，在中国南方和东南亚地区高发。EBV 靶向免疫疗法仍然是开发新型治疗策略的目标。一种新型的基于腺病毒多表位的免疫疗法已经被开发出来，以快速产生高频 EBV 特异性 T 细胞，用于治疗难治性或转移性疾病的患者。
Zotero 插件